Search results for: HTA
Filter search results
OHE Thanks Trustees for Their Service
17 December 2021
…more than 700 scientific papers. He has been President of both the International Society of Technology Assessment in Health Care (now HTAi), and the International Society for Pharmacoeconomics and Outcomes…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
…to shape the innovation agenda, adding an HTA value-based purchase commitment (building on earlier advance market and purchase commitments) to “push” based development funded in product development partnerships. Whilst the…
Accounting for Preference Heterogeneity in Discrete Choice Experiments
4 May 2022
…in Health, 25(5), 685–694. Related research Mott, D. J. (2018). Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind? The Patient, 11(3), 249–252. Mott, D….
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
…and Health Technology Assessment (HTA) initiatives, such as PRIME and the Joint Clinical Assessment (JCA); continuing to build Patient Groups capabilities to facilitate technical discussions on market access topics. In…
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
12 January 2014
…US and Europe. He identifies three sets of changes that must occur to meet the challenge: 1.A new drug development paradigm supported by regulatory authorities, HTA agencies and pharmaceutical companies…
How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
1 March 2019
…in the context of rare diseases: Bespoke data collection which is relevant to HTA decisionmakers; Simple economic modelling methods, which reflect the evidence available at the time of the assessment;…
Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
…and an increasing proportion of those are personalised medicines. By 2019, more than 260 drugs approved by the FDA included genomic information in the official labelling for use (Mehta, 2020)….
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
…commission a technical report (a joint clinical assessment) from an HTA body when these drugs applied for EMA approval. Member States would then vote on whether to proceed to negotiation…
Simon Brassel
4 March 2019
…estimate of the global burden of C-19, a description of the Digital Health Landscape in England and an assessment of the impact on NICE’s decisions on international HTA agencies. …